Company intelligence / Profile preview
IC-MedTech
- Ownership
- Private
- Development stage
- Preclinical
Overview
IC-MedTech has developed intellectual property around small molecule therapies that selectively target cellular redox processes in diseased cells. Their approach leverages both repurposed and novel compounds for oncology, infectious disease, inflammatory and genetic disease indications. The science remains emerging with no currently approved drugs from this platform; peer-reviewed publications support their rationale but there are no reported pivotal clinical results yet.
- Therapeutic areas
- OncologyImmunologyRare DiseasesInfectious Diseases
- Modalities
- Small moleculesFixed combination drugsRepurposed drugsNew chemical entities
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on IC-MedTech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IC-MedTech.